Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens - PubMed (original) (raw)
. 2008 Oct;36(10):1297-308.
doi: 10.1016/j.exphem.2008.05.002. Epub 2008 Jul 10.
Affiliations
- PMID: 18619726
- DOI: 10.1016/j.exphem.2008.05.002
Free article
Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens
Fei Fei et al. Exp Hematol. 2008 Oct.
Free article
Abstract
Objective: To investigate the inhibitory effects of dasatinib on proliferation, function, and signaling events on CD8+T cells.
Materials and methods: Carboxyfluorescein diacetate succinimidyl ester and 5-bromo-2-deoxyuridine were used to detect proliferation and cell cycle of CD8+T cells treated with dasatinib, respectively. Frequency and function of viral and leukemia-antigen-specific CD8+T cells from healthy donors were measured by tetramer staining and ELISPOT assay. Western blotting analysis was performed to detect T-cell receptor (TCR), nuclear factor kappa B (NF-kappaB) and Src signaling events in T cells treated with dasatinib or imatinib.
Results: Dasatinib inhibited proliferation of CD8+T cells in a dose-dependent manner, which was associated with lower secretion of interferon-gamma and granzyme B, as well as with arrest of CD8+T cells in the G0/G1 phase of cell cycle. Inhibition of CD8+T cells was proven for blood samples from a patient under dasatinib medication when compared with their T-cell status without dasatinib. Western blotting confirmed that these effects were mediated through downregulation of the phosphorylation level of molecules from the TCR and the NF-kappaB signaling transduction cascade. Dasatinib proved to be more potent than imatinib on Src and TCR signaling events in Jurkat T cells.
Conclusion: Our study demonstrated that dasatinib impaired proliferation and function of CD8+T cells via TCR and NF-kappaB signaling events without inducing apoptosis. Therefore, dasatinib might alter the graft-vs-leukemia effect and the graft-vs-host disease after allogeneic stem cell transplantation sustained by CD8+T cells. Dasatinib might also be used as a novel immunosuppressant agent.
Similar articles
- Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.
Nerreter T, Distler E, Köchel C, Einsele H, Herr W, Seggewiss-Bernhardt R. Nerreter T, et al. Exp Hematol. 2013 Jul;41(7):604-614.e4. doi: 10.1016/j.exphem.2013.02.013. Epub 2013 Mar 4. Exp Hematol. 2013. PMID: 23466625 - Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.
Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Götz M, Döhner H, Bunjes D, Schmitt M. Fei F, et al. Br J Haematol. 2009 Jan;144(2):195-205. doi: 10.1111/j.1365-2141.2008.07433.x. Epub 2008 Nov 7. Br J Haematol. 2009. PMID: 19016717 - Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD. Fraser CK, et al. Exp Hematol. 2009 Feb;37(2):256-65. doi: 10.1016/j.exphem.2008.09.013. Epub 2008 Dec 3. Exp Hematol. 2009. PMID: 19056158 - Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
Uchiyama T, Sato N, Narita M, Yamahira A, Iwabuchi M, Furukawa T, Sone H, Takahashi M. Uchiyama T, et al. Hematol Oncol. 2013 Sep;31(3):156-63. doi: 10.1002/hon.2034. Epub 2012 Oct 29. Hematol Oncol. 2013. PMID: 23108877
Cited by
- Cytomegalovirus US28 regulates cellular EphA2 to maintain viral latency.
Wass AB, Krishna BA, Herring LE, Gilbert TSK, Nukui M, Groves IJ, Dooley AL, Kulp KH, Matthews SM, Rotroff DM, Graves LM, O'Connor CM. Wass AB, et al. Sci Adv. 2022 Oct 28;8(43):eadd1168. doi: 10.1126/sciadv.add1168. Epub 2022 Oct 26. Sci Adv. 2022. PMID: 36288299 Free PMC article. - T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells.
van Bruggen JAC, Peters FS, Mes M, Rietveld JM, Cerretani E, Cretenet G, van Kampen R, Jongejan A, Moerland PD, Melenhorst JJ, van der Windt GJW, Eldering E, Kater AP. van Bruggen JAC, et al. Blood Adv. 2024 Sep 10;8(17):4633-4646. doi: 10.1182/bloodadvances.2023011934. Blood Adv. 2024. PMID: 39042920 Free PMC article. - Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib.
Liu G, Jin Z, Lu X. Liu G, et al. Int J Mol Sci. 2020 Mar 27;21(7):2337. doi: 10.3390/ijms21072337. Int J Mol Sci. 2020. PMID: 32230980 Free PMC article. - The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells.
Dörfel D, Lechner CJ, Joas S, Funk T, Gutknecht M, Salih J, Geiger J, Kropp KN, Maurer S, Müller MR, Kopp HG, Salih HR, Grünebach F, Rittig SM. Dörfel D, et al. Cancer Immunol Immunother. 2018 May;67(5):775-783. doi: 10.1007/s00262-018-2129-9. Epub 2018 Feb 21. Cancer Immunol Immunother. 2018. PMID: 29468363 Free PMC article. - Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.
Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Davis JS, et al. Clin Microbiol Rev. 2020 Jun 10;33(3):e00035-19. doi: 10.1128/CMR.00035-19. Print 2020 Jun 17. Clin Microbiol Rev. 2020. PMID: 32522746 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous